# Narration and storyboard draft: MOTS-c as a Metabolic Healthspan Peptide

Authored draft, approximately 60–90 seconds; no rendered video claimed.

MOTS-c is a short peptide whose proposed coding sequence lies inside mitochondrial12S-ribosomalRNA. That makes its genomic origin interesting, but it does not prove the mitochondrial ribosome produces the native peptide. The original study instead inferred cytoplasmic translation. In controlled mouse and rat experiments, supplied MOTS-c can improve selected glucose, muscle and cardiac outcomes. Older male mice also showed better grip, gait and walking after intermittent late-life treatment. Their overall lifespan curve, however, was not significantly extended. Human studies mostly measure peptide after exercise or during metabolic disease. They do not administer native MOTS-c and demonstrate durable healthspan benefit. The biology also has boundaries: responses differ by sex, tissue and peptide variant, and signaling activation can coexist with poorer cell repair. Our HSEFv5.3 review therefore retains context-specific preclinical benefit while grading the human treatment claim as mechanistically plausible with partial system support. The decisive next step is validated native-peptide exposure, a registered human functional trial and independent confirmation of safety and durable benefit.

1. Show the exact claim, grade and confidence.
2. Show selected publication milestones; label experimental systems and clinical endpoints.
3. Contrast the strongest result with its source-specific limitation.
4. End with the boundary experiment and primary-source links.

Use authored schematics; do not depict Consensus meters as causal confidence or reproduce publisher graphics without appropriate permission.